Nucleic acids encoding recombinant 56 and 82 kDa antigens from gametocytes of
View Patent ↗The present invention provides the recombinant cloning and sequencing of two of the major Eimeria maxima gametocyte antigens having molecular weights of 56 and 82 kDa and the expression of these recombinant antigens in an E. coli expression system using the plasmid pTrcHis. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen. The subject invention also provides two 30 kDa proteins and three 14 kDa proteins from Eimeria maxima gametocytes having at the N-terminal end the amino acid sequence described herein. The subject invention also provides a vaccine against coccidiosis comprising the recombinant 56 kDa or 82 kDa antigen and any of the aforementioned proteins. Additionally, the subject invention also provides a method of immunizing a subject against infection by Eimeria tenella, Eimeria maxima, Eimeria acervulina, Eimeria necatrix, Eimeria praecox, Eimeria mitis or Eimeria brunetti , or a microorganism expressing an immunologically cross-reactive antigen, comprising the step of administering to the subject any of the aforementioned vaccines.
1. An isolated nucleic acid sequence comprising a nucleotide sequence encoding a 56 kDa polypeptide having the amino acid sequence set forth as SEQ. ID. NO. 3 present in gametocytes of Eimeria maxima, or the full complement of the nucleic acid.
2. An isolated vector comprising an isolated nucleotide sequence encoding a 56 kDa polypeptide having the amino acid sequence set forth as SEQ. ID. NO. 3 present in gametocytes of Eimeria maxima, or the full complement of the nucleic acid.
3. An isolated host cell comprising an isolated vector comprising an isolated nucleotide sequence encoding a 56 kDa polypeptide having the amino acid sequence set forth as SEQ. ID. NO. 3 present in gametocytes of Eimeria maxima, or the full complement of the nucleic acid.
4. A method of producing a 56 kDa polypeptide present in gametocytes of Eimeria maxima comprising culturing isolated host cells comprising an isolated nucleotide sequence encoding a 56 kDa polypeptide having the amino acid sequence set forth as SEQ. ID. NO. 3 and isolating the 56 kDa polypeptide from the cells so cultured.
5. A vaccine for immunizing a subject against infection by Eimeria maxima comprising an isolated nucleic sequence encoding a 56 kDa polypeptide having the amino acid sequence set forth as SEQ. ID. NO. 3 present in gametocytes of Eimeria maxima or the full complement of the nucleic acid.
6. A method of immunizing a subject against infection by Eimeria maxima comprising administering to the subject the vaccine of claim 5 .
7. The isolated nucleic acid of claim 1 , wherein the nucleotide sequence is set forth as SEQ ID NO: 1.
8. The isolated nucleic acid of claim 1 , wherein the isolated nucleic acid is a plasmid designated 56TRCHisbl plasmid deposited under Australian Government Analytical Laboratories Accession No. NM01/122400.
9. The nucleic acid of claim 1 , wherein the nucleic acid is a DNA molecule or an RNA molecule.
10. The nucleic acid of claim 9 , which is a cDNA molecule.
11. The nucleic acid of claim 1 , further comprising an operatively linked promoter.
12. The vector of claim 2 , wherein the vector is a plasmid.
13. The host cell of claim 3 , wherein the cell is a bacterial cell, a plant cell, an insect cell, or a mammalian cell.
14. An isolated transformed cell comprising an isolated nucleotide sequence encoding a 56 kDa polypeptide having the amino acid sequence set forth as SEQ. ID. NO. 3 present in gametocytes of Eimeria maxima or the full complement of the nucleic acid.
15. The transformed cell of claim 14 , wherein the cell is designated clone 56TRCHisbl bacteria deposited under Australian Government Analytical Laboratories Accession No.NM01/22401.
16. The vaccine of claim 5 , wherein the subject is an avian species.
17. The vaccine of claim 16 , wherein avian species is chickens, ducks, turkeys, geese, bantams, quail, or pigeons.
18. The vaccine of claim 5 , wherein the vaccine is designed to be administered by intravenous, intramuscular or intraperitoneal injection; or by spraying said vaccine into the nostrils of the subject.
19. The vaccine of claim 17 , wherein the vaccine is designed to be administered in ovo.
20. The vaccine of claim 17 , wherein the vaccine is designed to be administered to an air sac of an egg.